Meloxicam CAS NO:71125-38-7

Indroduce

Meloxicam is suitable for symptomatic treatment of pain, swelling, soft tissue inflammation, traumatic pain and post-operative pain in rheumatoid arthritis and osteoarthritis.

Clinical application

1. oral administration

(1) Osteoarthritis 7.5 mg a day, one-time use, the maximum dose of 15 mg a day;

(2) Ankylosing spondylitis and rheumatoid arthritis 15 mg a day, twice a day, can also be reduced to 7.5 mg a day. The maximum daily dose for adults was 15 mg and that for the elderly was 7.5 mg.

2. Rectal administration

(1) Osteoarthritis, 7.5-15 mg, was inserted into the anus before bedtime;

(2) Ankylosing spondylitis and rheumatoid arthritis, 15 mg or 7.5 mg, were inserted into the anus before bedtime. The elderly 7.5 mg, before going to bed into the anus.

3. Other
Children under the age of 15 are not recommended.

Adverse reactions

Including gastrointestinal reactions (common dyspepsia, nausea, abdominal pain or diarrhea; rare ulcers, bleeding or perforation); anemia, leukopenia or thrombocytopenia, itching, rash; stomatitis; mild dizziness, headache; edema, elevated blood pressure, etc. Common elevated liver enzymes (10%) and occasional renal damage (0.4%). Most disappear after stopping the drug.

Medication contraindication

The following conditions are forbidden: patients with asthma, nasal polyps, angioneurotic edema or urticaria after the use of aspirin or other non-steroidal anti-inflammatory drugs; patients with active peptic ulcer, severe hepatic insufficiency, severe renal insufficiency in non-dialysis patients; patients with gastrointestinal hemorrhage, cerebral hemorrhage or other hemorrhage; patients with severe uncontrolled heart failure; children and years Teenagers under 15 years of age, pregnant women or breastfeeders.

Drug Interaction

1. Combination with methotrexate can increase the blood toxicity of methotrexate.

2. Combination of oral anticoagulant and thrombolytic agents may increase bleeding.

3. It can reduce the antihypertensive and diuretic effects of beta-adrenergic receptor blockers, angiotensin-converting enzyme inhibitors, loop diuretics (except furosemide), thiazide drugs.

4. Combined with potassium-preserving diuretics to reduce diuresis may lead to hyperkalemia or toxic kidney damage.

5. When combined with cyclosporine, the risk of cyclosporine poisoning increased.

6. When combined with levofloxacin and ofloxacin, the risk of seizures increased.

Note: The above contents are only for introduction. Drug use must be carried out under the guidance of doctors in regular hospitals.